TCRX

+ Watchlist + Portfolio

TScan Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.32
52-Week Range: $0.29 – $2.57
Market Cap: $20.94M
P/E (TTM): —
EPS (TTM): -0.91
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.31
PEG Ratio: —
Return on Equity: -95.80%
Return on Assets: -31.53%
Gross Margin: 0.00%
Operating Margin: -2901.33%
Profit Margin: 0.00%
Current Ratio: 3.37
Debt/Equity: 1.32
Total Debt: $90.89M
Free Cash Flow: $-79.92M
Revenue Growth: -65.80%
Earnings Growth: —
Enterprise Value: $12.46M

TCRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$13.54M	$21.05M	$2.82M	$10.32M
Research & Development	$59.82M	$88.15M	$107.35M	$114.15M
Selling, General & Admin	$20.35M	$25.49M	$29.56M	$31.33M
Operating Expenses	$80.17M	$114.51M	$137.64M	$146.14M
Operating Income	-$66.64M	-$93.46M	-$134.82M	-$135.81M
EBITDA	-$59.91M	-$80.10M	-$119.74M	-$124.13M
Pretax Income	-$66.22M	-$89.22M	-$127.50M	-$129.77M
Net Income	-$66.22M	-$89.22M	-$127.50M	-$129.77M
Diluted EPS	-2.75	-1.36	-1.14	-1.00
Diluted Shares	24.05M	65.60M	111.99M	129.78M

TCRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$120.03M	$133.36M	$178.69M	$152.41M
Current Assets	$124.13M	$194.24M	$292.72M	$157.21M
Total Assets	$199.09M	$272.15M	$371.12M	$228.79M
Current Liabilities	$17.30M	$29.82M	$35.96M	$18.70M
Long-Term Debt	$29.29M	$26.70M	$32.07M	$32.53M
Total Debt	$85.98M	$92.43M	$97.38M	$94.14M
Total Liabilities	$99.66M	$121.28M	$130.15M	$105.67M
Retained Earnings	-$158.38M	-$247.60M	-$375.10M	-$504.86M
Shareholders' Equity	$99.43M	$150.87M	$240.97M	$123.12M
Working Capital	$106.82M	$164.42M	$256.77M	$138.51M

TCRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$66.50M	-$61.36M	-$110.82M	-$135.32M
Capital Expenditure	-$4.22M	-$3.15M	-$3.83M	-$4.41M
Free Cash Flow	-$70.73M	-$64.50M	-$114.65M	-$139.73M
Depreciation & Amortisation	$5.14M	$5.36M	$4.11M	$2.87M
Stock-Based Compensation	$4.55M	$5.21M	$9.55M	$11.71M
Investing Cash Flow	-$4.22M	-$60.76M	-$52.61M	$109.37M
Financing Cash Flow	$29.36M	$135.44M	$208.76M	-$336.00K
Dividends Paid	—	—	$0.00	$0.00
Net Change in Cash	-$41.37M	$13.33M	$45.33M	-$26.28M

TCRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$2.17M	$3.08M	$2.51M	$2.57M	$982.00K	$1.05M
Research & Development	$29.79M	$32.63M	$31.69M	$20.04M	$21.90M	$23.40M
Selling, General & Admin	$8.46M	$8.92M	$7.70M	$5.73M	$8.13M	$8.06M
Operating Expenses	$38.42M	$41.73M	$39.56M	$26.43M	$30.12M	$31.54M
Operating Income	-$36.25M	-$38.65M	-$37.05M	-$23.86M	-$29.14M	-$30.49M
EBITDA	-$32.77M	-$35.56M	-$34.24M	-$21.55M	-$27.28M	-$28.96M
Pretax Income	-$34.13M	-$36.95M	-$35.71M	-$22.98M	-$28.67M	-$30.36M
Net Income	-$34.13M	-$36.95M	-$35.71M	-$22.98M	-$28.67M	-$30.36M
Diluted EPS	-0.26	-0.28	-0.28	-0.18	-0.22	-0.23
Diluted Shares	129.68M	129.73M	129.84M	129.86M	129.91M	129.95M

TCRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$154.11M	$169.39M	$169.51M	$152.41M	$128.06M	$100.16M
Current Assets	$254.84M	$221.13M	$188.16M	$157.21M	$132.77M	$104.40M
Total Assets	$332.71M	$298.56M	$262.23M	$228.79M	$201.99M	$171.45M
Current Liabilities	$29.82M	$31.32M	$29.21M	$18.70M	$19.97M	$30.96M
Long-Term Debt	$32.18M	$32.30M	$32.41M	$32.53M	$32.65M	$21.07M
Total Debt	$97.04M	$96.70M	$95.62M	$94.14M	$92.54M	$90.89M
Total Liabilities	$122.51M	$121.85M	$118.20M	$105.67M	$105.07M	$102.43M
Retained Earnings	-$409.22M	-$446.18M	-$481.88M	-$504.86M	-$533.53M	-$563.89M
Shareholders' Equity	$210.20M	$176.71M	$144.02M	$123.12M	$96.92M	$69.02M
Working Capital	$225.02M	$189.81M	$158.96M	$138.51M	$112.80M	$73.44M

TCRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$37.59M	-$33.27M	-$32.46M	-$32.00M	-$24.28M	-$27.54M
Capital Expenditure	-$1.53M	-$1.28M	-$1.43M	-$171.00K	-$70.00K	-$493.00K
Free Cash Flow	-$39.12M	-$34.55M	-$33.89M	-$32.17M	-$24.35M	-$28.03M
Depreciation & Amortisation	$678.00K	$698.00K	$767.00K	$723.00K	$693.00K	$699.00K
Stock-Based Compensation	$3.41M	$3.27M	$3.01M	$2.01M	$2.46M	$2.36M
Investing Cash Flow	$13.53M	$48.44M	$32.58M	$14.83M	-$70.00K	-$465.00K
Financing Cash Flow	-$525.00K	$116.00K	$0.00	$73.00K	$0.00	$99.00K
Dividends Paid	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$24.58M	$15.29M	$112.00K	-$17.10M	-$24.35M	-$27.90M

Market Snapshot

About

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing T cell receptor-engineered T cell (TCR-T) therapies for the treatment of cancer. The company uses its proprietary technology platform to identify novel cancer targets and engineer T cells to recognize and destroy tumor cells. TScan focuses on addressing both solid tumors and hematologic malignancies.